RedHill Biopharma Ltd.
RDHL
Rank in Stocks
#32746
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its... RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Share Price
$0.395
Last synced: 2026-11-09
Market Cap
$1.24M
Change (1 day)
-7.69%
Change (1 year)
-61.27%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade RedHill Biopharma Ltd. (RDHL)
Category
Healthcare
Operating Margin for RedHill Biopharma Ltd. (RDHL)
Operating Margin as of November 2026 TTM: -2,765.38%
According to RedHill Biopharma Ltd.'s latest financial reports, its current operating margin (TTM) is -2,765.38%. At the end of 2025 the company had an operating margin of -2,765.38%.
Operating Margin history for RedHill Biopharma Ltd. from 2010 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -2,765.38% | 0.00% |
| 2025 | -2,765.38% | 1,422.03% |
| 2024 | -181.69% | -193.92% |
| 2023 | 193.45% | -379.03% |
| 2022 | -69.33% | -26.72% |
| 2021 | -94.61% | -4.39% |
| 2020 | -98.95% | -85.59% |
| 2019 | -686.71% | 45.96% |
| 2018 | -470.47% | -63.73% |
| 2017 | -1,297.03% | -95.71% |
| 2016 | -30,240.59% | -95.88% |
| 2015 | -733,400.00% | 483,035.70% |
| 2014 | -151.80% | -99.83% |
| 2013 | -89,766.67% | 58.88% |
| 2012 | -56,500.00% | 65.06% |
| 2011 | -34,230.43% | 0.00% |
| 2010 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -100.01% |
DE
|
|
| 19.68% | -100.01% |
DE
|
|
| 13.26% | -100.00% |
JP
|
|
| 17.08% | -100.01% |
CH
|
|
| 14.92% | -100.01% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about RedHill Biopharma Ltd.'s operating margin
What is RedHill Biopharma Ltd.'s operating margin?
RedHill Biopharma Ltd.'s operating margin is -2,765.38%, as of Nov 2026.
What was RedHill Biopharma Ltd.'s operating margin in 2025?
In 2025, RedHill Biopharma Ltd.'s operating margin was -2,765.38%, compared with -181.69% in 2024.
How has RedHill Biopharma Ltd.'s operating margin changed since 2020?
From 2020 to 2025, RedHill Biopharma Ltd.'s operating margin was highest in 2023 (193.45%) and lowest in 2025 (-2,765.38%).
How does RedHill Biopharma Ltd.'s operating margin compare with similar companies?
RedHill Biopharma Ltd.'s operating margin (-2,765.38%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.